To date, much of the research on the clinical management of hereditary breast and ovarian cancer syndrome has focused on carriers of germline BRCA1 or BRCA2 mutations [1]. The gene discussed is BRCA1; the disease is Hereditary breast and ovarian cancer syndrome.